ClinicalTrials.gg
Not yet recruitingNCT07946783Updated Nov 18, 2026

A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

A Phase 1 interventional study of Single-ascending Dose (SAD) study and Food Effect (FE) study and Multiple-ascending Doses (MAD) study in Obesity With Cardiovascular Risk Study, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
99th of 169
103 · median 180
Started
2026
with 40 others
Phase 1
33 of 188
15 open now
Primary completion
2027-09
later than 29 of 73 live
Registered
188th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 99th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 29 of the 73 other live ones, and was the 188th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.

03

Conditions studied

  • Obesity With Cardiovascular Risk Study

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- i, Healthy adult participants, regardless of gender, aged between 18 and 65 years old when the is signed; ii,Male participants with a body weight of >= 50.0 kg, female participants with a body weight of >= 45.0 kg; iii, Those who can understand the informed consent form, voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with allergic constitution, or those with a history of food, drug allergies or other allergic reactions as determined by the investigators; or those who are known to be allergic to NLRP3 inhibitors or to the ingredients of the IP;
  2. Have any prior diagnosis of diabetes mellitus;
  3. Those with a positive result in any of the following tests: antibody, syphilis spirochete antibody, surface antigen, antibody, or interferon-gamma release assay;
  4. Those who donated blood or lost blood >=400 mL within 30 days prior to screening, or received blood transfusion;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
103 participants (estimated)

Study arms

  • Experimental
    Single-ascending Dose (SAD) study and Food Effect (FE) study

    Drug: Single-ascending Dose (SAD) study and Food Effect (FE) study

  • Experimental
    Multiple-ascending Doses (MAD) study

    Drug: Multiple-ascending Doses (MAD) study

  • Experimental
    Obesity with cardiovascular risk study

    Drug: Obesity with cardiovascular risk study

Interventions

  • DrugSingle-ascending Dose (SAD) study and Food Effect (FE) study

    The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts.

  • DrugMultiple-ascending Doses (MAD) study

    The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts.

  • DrugObesity with cardiovascular risk study

    This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    including hematology, blood biochemistry, urinalysis, and coagulation function

    Time frame: Day 1 to Day 21

Secondary outcomes

  1. ZL65 Pharmacokinetics (PK):Cmax

    Time frame: 0-144 hours

  2. ZL65 Pharmacokinetics (PK):Tmax

    Time frame: 0-144 hours

  3. ZL65 Pharmacokinetics (PK):AUC0-t

    Time frame: 0-144 hours

  4. ZL65 Pharmacokinetics (PK):t1/2

    Time frame: 0-144 hours

07

Study locations

1 site
  • Nucleus Network Pty Ltd Commercial Road
    Melbourne, Australia
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2027, 10 months later.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 10 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 19, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946783
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 19, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Sun Haibin
Contact
sunhaibin@zenitar.cn
+8618200237928
Ofer Gonen, Doctor
principal investigator · Nucleus Network Pty Ltd Commercial Road

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion